Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
Home > How Our Patients Perform > Anaplastic Oligodendroglioma   
How Our Patients Perform : Anaplastic Oligodendroglioma [AO]
Overall survival rates and a realistic evaluation of how UCLA Neuro-Oncology cares for patients with a Anaplastic Oligodendroglioma
What is a Anaplastic Oligodendroglioma
What is the Average Survival of a Newly Diagnosed AO Patient treated by UCLA Neuro-Oncology
What are the first steps of treatment for a Anaplastic Oligodendroglioma tumor
What chemotherapy agents does UCLA Neuro-Oncology use to treat patients with a Anaplastic Oligodendroglioma tumor
How much experience does UCLA Neuro-Oncology have treating Anaplastic Oligodendroglioma patients
What are the Advantages of being treated at a University Medical Center
What CLINICAL TRIALS are available for Anaplastic Oligodendroglioma Patients
How do I Refer a Anaplastic Oligodendroglioma Patient to UCLA
What is Anaplastic Oligodendroglioma tumor?
An oligodendroglioma with focal or diffuse histological features of malignancy and a less favorable prognosis.

J Neurooncol. 2003 Sep;64(3):271-8.

What is the Average Survival of a Newly Diagnosed Anaplastic Oligodendroglioma Patient treated by UCLA Neuro-Oncology?
There are several key factors that influence overall survival of a Anaplastic Oligodendroglioma patient, these include initial diagnosis, number of times the tumor has recurred, patient age, molecular diagnostic results, past therapy, Karnofsky Score, tissue features, along with 50-60 other key variables. It is the job of the Neuro-Oncologist to take into account all factors and formulate the best option for you and your family.

Although it can be difficult to predict survival using just a single variable of pathology diagnosis, in general the following represents the average overall survival of Initially Diagnosed AO patients treated by UCLA Neuro-Oncology. The patients represented all have started treatment ON or AFTER 5/28/2009.

Kaplan-Meier Plot (Est. Survival)

The Kaplan-Meier, estimates the survival function from life-time data. In the research setting it's used to measure the fraction of patients living from the time of initial diagnosis.

A plot of the Kaplan-Meier estimate of the survival function is a series of horizontal steps of declining magnitude which, when a large enough sample is taken, approaches the true survival function for that population. The value of the survival function between successive distinct sampled observations ("clicks") is assumed to be constant.

An important advantage of the Kaplan-Meier curve is that the method can take into account "censored" data — losses from the sample before the final outcome is observed. On the plot, small vertical tick-marks indicate losses, where patient data has been censored. When no truncation or censoring occurs, the Kaplan-Meier curve is equivalent to the empirical distribution.

* Published: Saturday, May 28, 2016 : 8:49:36 PM PT

What are the first steps of treatment of a Anaplastic Oligodendroglioma tumor?

There are important first steps a patient must take in order to maximize the chances of survival and a successful therapy.
First Steps of Treatment:
Dr. Timothy Cloughesy explains the first steps of Neuro-Oncology Care, and outlines UCLA's Multi-disciplinary approach to effectively treat brain tumor patients

First one needs to clarify and confirm the pathologic diagnosis. This pathologic diagnosis is made based on the tissue obtained from the initial surgery. Going forward, the treatment plan will be created based on this diagnosis. This formal diagnosis is made by the neuro-pathologists and is the most important piece of information of any treatment plan.

It is important to note that it is critical to save all tumor tissue collected at the initial surgery. Not only for pathologic diagnosis but also many clinical trials down the road will require frozen tissue from the initial surgery.

Next we want to make sure the pathology diagnosis matches what we see on the MRI scan and what is going on with the patient. Taking all of these data points into consideration helps us get a better picture of what is going on with the patient, and can help us better determine how to move forward.

Once we are sure about the diagnosis we can move forward with Treatment Options. Sometimes the treatment will include a more extensive surgery in order to maximize the total resection of the tumor. In higher grade tumors, treatment options can include Radiation Therapy alone, combination therapy of Radiation and Chemotherapy, or combination therapy of Radiation and Chemotherapy followed by additional Chemotherapy.

The decision of what therapy to administer is provided by the Neuro-Oncologists.

If traditional therapy fails in the newly diagnosed setting, additional therapy can be administered in the recurrent setting.

The treatment approaches in the recurrent setting mirror some of the options in the newly diagnosed setting. For example, we will need to identify if the patient needs additional surgery for de-bulking or further tumor resection. The neuro-oncologist will also need to identify if further radiation is needed. Most of the time in these recurrent settings additional systemic treatment will need to occur. These forms of treatment can be either standard chemotherapy agents or experimental therapies as part of an ongoing clinical trial.

What chemotherapy agents does UCLA Neuro-Oncology use to treat patients with a AO tumor?
Because each patient's treatment plan is unique, therapy normally is dictated by several factors including a person’s age, Karnofsky Score and any previous therapy they have received. Advances in our molecular diagnostics lab is enabling us to better predict what agents will benefit a particular patient group. In general, the following is an overview of agents we used to treat our AO patients during the past 24 months. This list includes all patients treated at UCLA Neuro-Oncology between 5/28/2014 and 5/28/2016.
• Accutane Hoffmann-La Roche• Avastin (Bevacizumab) Genetech• Carboplatin
• CCNU Lomustine• CPT -11 (CAMPTOSAR, Irinotecan)• Etoposide (Eposin, Etopophos, Vepesid)
• GLIADEL Wafer• Iressa (ZD-1839)• PCV
• Poly ICLC• Procarbazine• Rapamycin (Rapamune, Sirolimus)
• Tamoxifen• TEMODAR Schering-Plough• Thalomid (thalidomide)
• Vincristine

* Published: Saturday, May 28, 2016 : 8:49:36 PM PT

How much experience does UCLA Neuro-Oncology have treating patients with a Anaplastic Oligodendroglioma tumor?
A patient's tumor can often change from a lower grade tumor to a high grade tumor within a period of 24 months. In general the number of patients we treat with a diagnosis of Glioblastoma Multiforme at the time of therapy, based on data covering 5/28/2014 to 5/28/2016 are as follows:

What is the demographic breakdown of Anaplastic Oligodendroglioma patients treated by UCLA Neuro-Oncology?
In general the number of patients we have treated with a diagnosis of Anaplastic Oligodendroglioma at the time of treatment, based on data covering 5/28/2014 to 5/28/2016 are as follows:

What are the Advantages of being treated at a University Medical Center.
University Medical Centers specializing in the treatment of brain tumors have several advantages over community treatment centers and most private hospitals.
Treatment at a University Medical Center:
Dr. Timothy Cloughesy explains the importantce of receving treatment at a University Medical Center and the critical advantage patients may gain.
One of the areas where patients receive a benefit is in the tumor resection. At UCLA, the neuro-surgical teams not only use the most advanced surgical tools and robotic assisted machines, but at UCLA they also use Intra-Operative MRIs.  An intra-operative MRI is important because it ensures the maximum amount of tumor will be safely removed.
Another area where patients receive a significant benefit is having access to the newest clinical trials and experimental therapies.  At UCLA, researchers and physicians work closely with drug companies and national consortiums to secure state of the art chemotherapy agents for our patients.  In most cases UCLA is one of the first institutions to conduct phase I/II clinical trials for these agents.
UCLA also aims to provide the best possible care by using a Multi-Disciplinary approach to therapy. This means that specialist in Neurology, Neuro-Surgery, Radiation Oncology, Neuro-Radiology, Pathology and Neuro-Oncology are all involved when formulating your treatment plan.
Another advantage that can not be over looked is that UCLA researchers and physicians who treat primary brain tumors sole focus is brain tumor patients. The UCLA Neuro-Oncologists and other members of our team are focused 100% on brain tumor patients. They are required to be leaders in the field in terms of research and clinical care. They are also required to attend national conferences and publish regularly on their findings. Their goal is not only to help treat patients with primary brain tumors, but also push science forward towards a cure.

What clinical trials are available at UCLA Neuro-Oncology?
Choosing to participate in a clinical trial is an important, personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521

Study AgentIRB IDTrial:Details
15-001680[ABTC 14-02]:
MEDI473614-001460[Ludwig LUD2013-006]:
5-FC (Flucytosine)10-001147[Tg 511-09-01]:
ACP-19615-001667[Acerta ACE-ST-209]:
aCTL and IL-211-000790[aCTL Immunotherapy (Dr Liau)]:
CDX-110, Temozolomide11-002220[Celldex CDX110-05] :
Lapatinib (GW572016), TMZ, RT12-000493[Lapatinib_Nghiemphu]:
MK-347515-000148DFCI MK3475:
Nivolumab, the combination of Nivolumab and ipilimumab14-000075[BMS CA209143]:
Toca 51115-001608[Tg 511-15-01]:
VB-11115-001545 VBL VB-111-215 :

How do I Refer a Anaplastic Oligodendroglioma Patient to UCLA.

At UCLA Neuro-Oncology we aim to provide the very best possible patient care to you, and would like to make contacting us as pleasant and efficient as possible.

If you are a physician:

If you would like to directly refer a patient to us for care or consultation, or would like to discuss the care of a patient with us, please feel free to telephone our main office at 310.825.5321. To directly schedule a new patient for an appointment please contact the NEW PATIENT SCHEDULING LINE: at 310-206-6909.

If you are a patient:

If you are new to us and are seeking to schedule a clinical visit, 2nd opinion visit, or have your scans, tissue or other resource evaluated you will need to contact the NEW PATIENT SCHEDULING LINE at 310-206-6909 to set up an appointment.

If you have previously been seen by us at UCLA Medical Center please call the RETURN VISIT SCHEDULING LINE at 310-206-9260 and they can assist you with scheduling or re-scheduling an appointment

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2016 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2016 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:5/28/2016 8:49:36 PM PST]